GLP-1 Receptor Agonists Consistently Reduce Major Adverse Cardiovascular Events Across Diverse Populations

Cardiovascular disease remains a leading cause of morbidity and mortality, particularly in individuals with type 2 diabetes and obesity. Traditional glucose-lowering therapies often fall short in providing comprehensive cardiovascular protection. The GLP-1 signaling pathway plays a crucial role in glucose homeostasis, but its broader vascular and myocardial effects, including improved endothelial function and reduced inflammation, highlight its potential beyond glycemic control. Understanding these multifaceted benefits is key to optimizing cardiometabolic care.

This clinical primer comprehensively reviewed the physiology of GLP-1 signaling, the extensive evidence supporting cardiovascular risk reduction, and practical considerations for the clinical use of incretin-based therapies. The authors synthesized findings from numerous large randomized cardiovascular outcomes trials (CVOTs) that investigated various GLP-1 receptor agonists in diverse patient populations, including those with established cardiovascular disease and individuals with obesity but without diabetes. The review also touched upon emerging dual incretin therapies.

GLP-1 receptor agonists consistently demonstrated significant cardiovascular benefits across multiple large randomized CVOTs. These agents were found to reduce major adverse cardiovascular events (MACE), encompassing myocardial infarction, stroke, cardiovascular death, and heart failure. Benefits were observed in both patients with established cardiovascular disease and those with obesity but without diabetes. Mechanistically, GLP-1 RAs improve endothelial function, reduce inflammation and oxidative stress, and induce favorable changes in cardiac metabolism and remodeling. Emerging dual GIP-GLP-1 RAs are anticipated to further extend these benefits. The collective evidence suggests a shift in the underlying metabolic milieu towards a more favorable physiological state.

Several GLP-1 RAs consistently reduced major adverse cardiovascular events, including myocardial infarction, stroke, cardiovascular death, and heart failure, across diverse populations.